Sysmex CZ & SK
Menu

OGT launches SureSeq™ Myeloid Plus panel and Universal NGS Complete Workflow

2022/11/03 – Oxford, United Kingdom

Launch of several new solutions to support OGT’s growing NGS portfolio


OGT (Oxford Gene Technology), a Sysmex Group Company, announces the recent launch of several new solutions to support its growing NGS portfolio. These include the SureSeq™ Myeloid Plus panel, which has been designed to detect aberrations in genes implicated in a variety of myeloid disorders. Additionally, OGT has also launched a new improved library preparation workflow—the OGT Universal NGS Complete Workflow, compatible with its haematology, inherited and rare disease NGS panels—significantly reducing hands-on time and complemented by updated Interpret NGS Analysis software.


The SureSeq Myeloid Plus panel is the most recent addition to OGT’s haematology NGS portfolio. Having been meticulously designed along-side leading cancer experts, the new panel is able to detect a comprehensive range of aberrations including SNVs, indels, ITDs and PTDs within 49 genes. These genes cover those associated with myeloid disorders including acute myeloid leukaemia, myeloproliferative neoplasms and myelodysplastic syndrome among others. Thanks to OGT’s vast expertise in bait design, the Myeloid Plus panel delivers unparalleled coverage uniformity for low frequency variants, even in difficult-to-sequence AT/GC rich regions and challenging regions covering ITDs and PTDs, which are common somatic variants in acute myeloid leukaemia (AML) often associated with poor prognosis and an aggressive form of the disease.

To support researchers using the SureSeq Myeloid Plus panel, and indeed all of OGT’s SureSeq haematology and CytoSure® NGS panels, the new Universal NGS Complete Workflow has been developed. By reducing the number of clean-up steps and QC requirements, library preparation can be completed in just four and a half hours, with a 40% saving of hands-on time. By combining several steps, and introducing sample pooling, the reduced workflow complexity not only decreases the potential for error, but also saves on plastic waste and costs. 

Compared to the previous SureSeq workflow, the updated version requires no additional expensive laboratory equipment, making the process much more amenable to automation, and therefore ready for the future. To supplement this new and improved workflow, OGT’s renowned Interpret NGS Analysis software (v3.5) has been upgraded with improvements in CNV interpretation, annotation, visualisation and sample data import and display. Unlike many other NGS providers, OGT provides complimentary NGS software with its NGS panels, demonstrating the company’s commitment to sharing technology, and technical expertise to support NGS research around the globe.

Adrian Smith, Chief Executive Officer of OGT, commented, “OGT are experts in delivering high efficiency NGS workflows with best-in-class gene panels, software, and library preparation solutions. Thanks to our unmatched expertise in bait design, and through partnering with leading cancer experts, we have developed a powerful tool for myeloid research with a highly efficient workflow. This enables clinical researchers to quickly and confidently detect all relevant variants in one simple assay. NGS is a key area of expertise for OGT, and we have exciting plans and possibilities for the future.”

 

About OGT

OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell®, CytoSure® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.

For more information on the company, please visit www.ogt.com

CytoCell® FISH probes are CE IVD for laboratory professional use only. Not intended for use as stand-alone diagnostics or companion diagnostics. Therapeutic action should not be initiated on the basis of the FISH result alone. CytoSure®, SureSeq™ and CytoCell myProbes®: For Research Use Only, not for use in diagnostic procedures. Product availability may vary from country to country and is subject to varying regulatory requirements. Contact your local representatives for availability.

                              

About Sysmex Europe SE

Sysmex supports healthcare professionals around the world in lighting the way with diagnostics by providing a broad range of medical diagnostics products and solutions. In the fields of haematology, urinalysis, haemostasis, life science, flow cytometry, essential healthcare and now immunochemistry, we combine highly dependable, multi-functional and easy-to-operate instruments, a variety of reagents and software, plus reliable service and support.

Sysmex Europe SE, located near Hamburg, Germany, is a subsidiary of the Sysmex Corporation from Kobe, Japan. From our Hamburg offices, we serve our affiliates, distributors and customers throughout Europe, the Middle East, and Africa (EMEA). For more information, visit www.sysmex-europe.com.

Copyright © Sysmex Europe SE. All rights reserved.